Focused On-demand Library for Vesicular glutamate transporter 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NDX2

UPID:

VGLU3_HUMAN

Alternative names:

Solute carrier family 17 member 8

Alternative UPACC:

Q8NDX2; B3KXZ6; B7ZKV4; Q17RQ8

Background:

Vesicular glutamate transporter 3 (VGLUT3), encoded by the gene with the accession number Q8NDX2, is a multifunctional transporter. It is pivotal in transporting L-glutamate and various ions like chloride, sodium, and phosphate across membranes. Its primary role at the synaptic vesicle membrane is as an uniporter facilitating L-glutamate uptake into synaptic vesicles, crucial for neurotransmission in excitatory neural cells. Additionally, VGLUT3 functions as a chloride channel and, following exocytosis, as a symporter for Na(+) and phosphate, aiding in synaptic phosphate homeostasis.

Therapeutic significance:

The association of VGLUT3 with autosomal dominant deafness, 25 (DFNA25), underscores its clinical relevance. This condition, characterized by non-syndromic sensorineural hearing loss, highlights the therapeutic potential of targeting VGLUT3. Understanding the role of VGLUT3 could open doors to potential therapeutic strategies for hearing loss and other neurological conditions.